Professor, Medicine, Geisel School of Medicine
Internal Medicine
Dr. Steven Woloshin, MD
|
|
Give Review
Steven Woloshin works in the field of Internal Medicine. He graduated from Boston University School of Medicine. Boston University School of Medicine is ranked 30/52 in Research/PrimaryCare. Steven Woloshin is a published doctor and has 101 publications published. The lastest was: 'Patients' Knowledge, Beliefs, and Distress associated with Detection and Evaluation of Incidental Pulmonary Nodules for Cancer: Results from a Multicenter Survey.'
Publications
- Patients' Knowledge, Beliefs, and Distress associated with Detection and Evaluation of Incidental Pulmonary Nodules for Cancer: Results from a Multicenter Survey.
- A Randomized Trial Testing US Food and Drug Administration "Breakthrough" Language.
- Attitudes about Low-Dose Computed Tomography Screening for Lung Cancer: A Survey of American Thoracic Society Clinicians.
- Cancer survival: an overview of measures, uses, and interpretation.
- When do changes in cancer survival mean progress? The insight from population incidence and mortality.
- Providing clinicians and patients with actual prognosis: cancer in the context of competing causes of death.
- US Food and Drug Administration and design of drug approval studies.
- Resource Use and Guideline Concordance in Evaluation of Pulmonary Nodules for Cancer: Too Much and Too Little Care.
- Promotion of "low t" and the role of testosterone clinical trials-reply.
- The New Weight-Loss Drugs, Lorcaserin and Phentermine-Topiramate: Slim Pickings?
- Using Radiology Reports to Encourage Evidence-based Practice in the Evaluation of Small Incidentally Detected Pulmonary Nodules: A Preliminary Study.
- Medical communication companies and continuing medical education: clouding the sunshine?
- Low "t" as in "template": how to sell disease.
- The Drug Facts Box: Improving the communication of prescription drug information.
- Accountable prescribing.
- Winding back the harms of too much medicine.
- How a charity oversells mammography.
- How the FDA forgot the evidence: the case of donepezil 23 mg.
- When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found.
- Authors' reply to Quantrill, Benger, Ripley and colleagues, Roach, Rogers, and Haldar and colleagues.
- Influence of medical journal press releases on the quality of associated newspaper coverage: retrospective cohort study.
- Too Little? Too Much? Primary care physicians' views on US health care: a brief report.
- Communicating uncertainties about prescription drugs to the public: a national randomized trial.
- Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records.
- Communicating data about the benefits and harms of treatment: a randomized trial.
- Time trends in pulmonary embolism in the United States: evidence of overdiagnosis.
- Not so silver lining.
- Breast cancer awareness month. Still awaiting screening facts.
- Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review.
- When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations.
- The benefits and harms of mammography screening: understanding the trade-offs.
- Bringing the FDA's Information to Market.
- Promoting healthy skepticism in the news: helping journalists get it right.
- Lost in transmission--FDA drug information that never reaches clinicians.
- Numbers needed to decide.
- Press releases by academic medical centers: not so academic?
- Using a drug facts box to communicate drug benefits and harms: two randomized trials.
- Flawed inferences about screening mammography's benefit based on observational data.
- Older patients perceptions of "unnecessary" tests and referrals: a national survey of Medicare beneficiaries.
- The risk of death by age, sex, and smoking status in the United States: putting health risks in context.
- The sea of uncertainty surrounding ductal carcinoma in situ--the price of screening mammography.
- A genetic risk factor for periodic limb movements in sleep.
- Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study.
- Implications of expanding disease definitions: the case of osteoporosis.
- Participation in mammography screening.
- The drug facts box: providing consumers with simple tabular data on drug benefit and harm.
- Direct-to-consumer advertisements for HIV antiretroviral medications: a progress report.
- Choosing where to have major surgery: who makes the decision?
- Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States.
- The effectiveness of a primer to help people understand risk: two randomized trials in distinct populations.
- Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks.
- Group writing of letters to the editor as the goal of journal club.
- Media reporting on research presented at scientific meetings: more caution needed.
- Giving legs to restless legs: a case study of how the media helps make people sick.
- Ramifications of screening for breast cancer: 1 in 4 cancers detected by mammography are pseudocancers.
- What's the rush? The dissemination and adoption of preliminary research results.
- Patients and medical statistics. Interest, confidence, and ability.
- How do elderly patients decide where to go for major surgery? Telephone interview survey.
- Reducing the risk that patients get it wrong.
- Skin biopsy rates and incidence of melanoma: population based ecological study.
- Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
- Can patients interpret health information? An assessment of the medical data interpretation test.
- Celebrity endorsements of cancer screening.
- Distribution of C-reactive protein values in the United States.
- The exaggerated relations between diet, body weight and mortality: the case for a categorical data approach.
- Advertising by academic medical centers.
- Screening for cervical cancer: will women accept less?
- Symptoms and treatment burden of gastroesophageal reflux disease: validating the GERD assessment scales.
- The value of benefit data in direct-to-consumer drug ads.
- Association of aspirin use and hormone receptor status with breast cancer risk.
- Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000.
- The media matter: a call for straightforward medical reporting.
- Enthusiasm for cancer screening in the United States.
- Making sense of risk information on the web.
- Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?
- On the prevention and treatment of exaggeration.
- Tobacco money: up in smoke?
- News media coverage of screening mammography for women in their 40s and tamoxifen for primary prevention of breast cancer.
- Risk charts: putting cancer in context.
- Media coverage of scientific meetings: too much, too soon?
- Press releases: translating research into news.
- Late outcomes after laparoscopic surgery for gastroesophageal reflux.
- Smoke-free movies: sense or censorship?
- Marketing medicine to the public: a reader's guide.
- Direct-to-consumer advertisements for prescription drugs: what are Americans being sold?
- Assessing values for health: numeracy matters.
- Women's views on breast cancer risk and screening mammography: a qualitative interview study.
- The case for letting information speak for itself.
- How many deaths are due to medical error? Getting the number right.
- US women's attitudes to false-positive mammography results and detection of ductal carcinoma in situ: cross-sectional survey.
- Invited commentary: early-stage breast cancer treatment for elderly women-does one size fit all?
- A new scale for assessing perceptions of chance: a validation study.
- Arguing about grades.
- Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data.
- Are increasing 5-year survival rates evidence of success against cancer?
- US women''s attitudes to false positive mammography results and detection of ductal carcinoma in situ: cross sectional survey.
- Risk communication in clinical practice: putting cancer in context.
- Women's understanding of the mammography screening debate.
- Patient decision making: in search of good decisions.
- How can we help people make sense of medical data?
Schools
Boston University School Of Medicine
Nyu Hospitals Center
Doctors Specialties
- Internal Medicine
Accepted Insurances
Education
-
NYU School of Medicine -
Boston University School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Lisa M. Schwartz, MD |
|
|
Dr. Kerry Vrakatitsis, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nancy Cochran, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexandra M. Grossman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert P. Mogielnicki, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lynn L. Webster, MD |
|
|
Dr. Brenda E. Sirovich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amanda W. Ratliff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory S. Ogrinc, MD
This Doctor is OpenDoctor Recommended.
|